<DOC>
	<DOCNO>NCT00381095</DOCNO>
	<brief_summary>The purpose study assess analgesic efficacy flexibly-dosed pregabalin adjunctive treatment subject cancer-induced bone pain .</brief_summary>
	<brief_title>A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer</brief_title>
	<detailed_description>Pfizer decide discontinue additional enrollment study effective Sept 5 2010 assess feasibility complete study realistic timeframe.The study stop safety concern .</detailed_description>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patient must malignant , solid tumor diagnose metastasized bone , must moderate severe pain secondary bone metastasis identifiable reference site . The patient undergone diagnostic therapeutic invasive intervention ( angiography , biopsy , surgery ) less 15 day prior study start would impact assessment pain reference pain site area , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>